D.J.Th. Wagener , R. Somers , A. Santoro , J. Verweij , P.J. Woll , G. Blackledge , H.J. Schütte , M.A. Lentz , M. van Glabbeke , European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
{"title":"尼莫司汀治疗转移性软组织肉瘤的II期研究","authors":"D.J.Th. Wagener , R. Somers , A. Santoro , J. Verweij , P.J. Woll , G. Blackledge , H.J. Schütte , M.A. Lentz , M. van Glabbeke , European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","doi":"10.1016/0277-5379(91)90424-C","DOIUrl":null,"url":null,"abstract":"<div><p>The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m<sup>2</sup> every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90424-C","citationCount":"4","resultStr":"{\"title\":\"Phase II study of nimustine in metastatic soft tissue sarcoma\",\"authors\":\"D.J.Th. Wagener , R. Somers , A. Santoro , J. Verweij , P.J. Woll , G. Blackledge , H.J. Schütte , M.A. Lentz , M. van Glabbeke , European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group\",\"doi\":\"10.1016/0277-5379(91)90424-C\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m<sup>2</sup> every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90424-C\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/027753799190424C\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190424C","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Phase II study of nimustine in metastatic soft tissue sarcoma
The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
